Clinical trial
A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma
NCT00100152 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 28, 2005
- Completion date
- October 31, 2006
- Enrollment
- 50
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia, leukemia, lymphoblastic, acute, t-cell, myelodysplastic syndromes, myelogenous leukemia